基于超顺磁Fe_3O_4的磁响应型纳米药物载体的研究进展

基于超顺磁Fe_3O_4纳米粒子(SPIONs)的磁响应型纳米药物载体已经广泛应用于肿瘤诊断与治疗方面。将SPIONs用多功能性外壳修饰后,能够增加其稳定性,实现体内长循环,并能缓释出所携带药物;将其与靶向性配体分子复合后,能够提高其肿瘤多靶向的效果;通过将SPIONs用温敏性或光敏性等外壳材料包覆,利用SPIONs的磁致发热、光致发热以及外壳材料自身的特点,能够直接杀死肿瘤细胞或者将温敏性外壳剥落,平稳地释放出药物,提高肿瘤部位的药物浓度,增强治疗效果。本文综述了基于超顺磁Fe_3O_4的磁响应型纳米药物载体在肿瘤治疗领域的新研究与新进展,以期为今后相关方面的深入研究提供参考和借鉴。     

基于肿瘤微环境响应的DNA纳米结构递药系统

DNA分子由于其独特的生物相容性和可编程性,在增强药物靶向性和降低药物毒性方面展现了独特的优势和巨大的潜力。随着人们对肿瘤微环境研究的深入和环境响应性的DNA触发器的研制,近些年已报道了许多基于肿瘤微环境响应的DNA纳米结构递药系统,这些DNA纳米结构递药系统结合了纳米运载工具良好的生物分布和药代动力学特性,以及小型药物载体的快速扩散和渗透特性。通过靶向广泛的肿瘤栖息地而不是肿瘤特异性受体,该策略有可能克服肿瘤异质性问题,并可用于设计诊断和治疗多种实体肿瘤的纳米颗粒。在体内能够稳定地转运,在肿瘤组织独特的微环境刺激下释放药物,能有效地控制药物释放部位和释放速度,极大地降低了肿瘤治疗的毒副作用。本文主要从pH响应型、GSH响应型、ATP响应型、酶响应型、抗原响应型五个方面,综述了基于肿瘤微环境响应的DNA纳米结构递药系统的最新研究进展,分类介绍了这些DNA纳米载体的设计策略和响应释放机制,此外,还重点介绍了该领域面临的前景和挑战。     

功能多肽在肿瘤治疗中的应用及研究进展

多肽具有生物相容性好,功能多样化,生物体内响应性高及合成修饰方法简单易行等优点,已被广泛用于构建靶向药物传递系统。以具有靶向功能和刺激响应性的多肽为基础构建的药物传递系统,能够将药物定向地运送到肿瘤区域。药物传递系统到达肿瘤组织后,在肿瘤组织特殊微环境或外源刺激下,实现药物的精准释放。这种具有特异性肿瘤靶向和刺激响应型的多肽载体可以最大程度地提高药物的抗肿瘤效果,降低药物的毒副作用。本文简要介绍了常用的靶向多肽和刺激响应型多肽,并讨论了基于功能型多肽的药物载体在肿瘤治疗方面的应用。     

温度敏感性药物载体及其在肿瘤热化疗中的应用

温度敏感性材料由于其理化性质对温度变化高度敏感,同时相变温度又易于调控,因而成为条件响应型药物控释载体中的研究热点。多种类型的温敏性药物载体,包括脂质体、聚合物囊泡、聚合物胶束,经过多年的研究和优化,其稳定性得到进一步的提高,而相变温度也实现了在较宽范围内的随意调整,可同时适用于病理性的高热和局部人工热疗等多种方式的温敏靶向性释药。并且,由于局部热疗可以有效控制温敏载体的药物释放,同时,热疗还能有效增强化疗药物的细胞毒性,因此温敏药物载体在肿瘤化疗和热化疗领域具有独特的应用潜力。本综述简要回顾了温敏性载体在药物载体领域的研究现状。在此基础上,从对肿瘤热化疗原理、发展现状、疗效影响因素的角度,进一步综述了温敏性药物载体在肿瘤热化疗领域的研究进展,特别关注了复合型温敏载体,因为这类载体结合了具有光热/磁热效应的纳米颗粒而兼具自升温能力,因而在靶向性热化疗中独具优势。最后,本文结合热化疗的影响因素,对温敏性载体在肿瘤热化疗领域的发展方向进行了展望。     

可控释放二氧化硫的高分子纳米药物

近年来,二氧化硫(SO₂)气体分子在肿瘤治疗领域展现出巨大的潜力.然而,传统的使用气体吸入或亚硫酸盐作为供体的方法难以应用于临床.本综述首先介绍了一系列能够响应性释放SO₂的有机小分子供体,梳理了这些小分子供体的化学结构及响应性释放方式.接着,回顾了近年来可控释放SO₂的高分子纳米药物在肿瘤治疗研究中的发展,简述了这些纳米药物的治疗机理及抗肿瘤效果.研究表明：将SO₂与高分子纳米载体技术相结合,解决了有机小分子供体存在水溶性差、肿瘤靶向性不佳等问题.制备的可控释放SO₂的高分子纳米药物能够实现在肿瘤部位的靶向富集及SO₂气体的可控释放,表现出良好的抗肿瘤治疗效果.最后,分析并指出了可控释放SO₂高分子纳米药物面临的挑战,并对其未来的发展进行了展望.     

基于透明质酸的刺激响应纳米给药系统的研究进展

透明质酸(Hyaluronic acid, HA)是一种天然多糖,具有良好的生物相容性和生物降解性,利用 HA 构建的纳米载体自身就具有肿瘤靶向功能,可以作为抗癌药物载体将药物传递到肿瘤细胞内从而实现精准到达病患处。近年来透明质酸在应用于肿瘤靶向给药系统中的关注越来越多,成为了靶向治疗肿瘤的一大研究热点。基于透明质酸的基本特性和肿瘤靶向的生理学基础,在不同的刺激响应下,透明质酸型纳米给药系统能将药物集中释放于肿瘤的微环境内,更好地杀死肿瘤细胞,同时避免其他正常的组织受到药物损害。本文主要综述了透明质酸型纳米药物输送系统在各种刺激响应下释放药物的最新研究进展。     

pH响应型纳米药物载体的释药机制及性能研究进展

pH响应型纳米载体因具有智能的酸敏或碱敏释药性能,已成为当前一类重要的多功能纳米载体,并得到了研究人员的广泛关注。特别是酸敏性纳米载体,可用于肿瘤弱酸微环境的药物控释,因而对药物的定点释放和癌症的靶向治疗等生物医学应用发挥了积极作用。本文综述了近年来各类pH响应型纳米载体的典型合成方法,系统地介绍了共价键、分子间作用力以及物理结构变化3种方式引发的pH响应释药机制。深入阐述了pH响应型纳米载体的载药性能、体外释药性能、体外细胞毒性、体内抗癌性能及体内分布性能,并详细列举了近年来pH响应型纳米载体的各类实验参数,进而为pH响应型纳米载体的深入研究提供了方法学的借鉴和性能参考。     

靶向肿瘤进化的创新纳米药物

近年来,随着纳米技术的发展,将纳米材料应用于肿瘤靶向治疗有望极大地改善肿瘤治疗效果.纳米药物因其可增加药物溶解性、延长血液循环时间、提高靶向性、提升治疗效果并降低毒副作用等特点而备受研究者关注.肿瘤生物学研究表明,肿瘤始终处于动态的进化和演化过程之中,由于其基因组的不稳定性,肿瘤细胞可在肿瘤内部的生存压力下进行自然选择,或在外来治疗压力(放射治疗、化学治疗、分子靶向治疗和免疫治疗)作用下,持续产生基因突变并扩增,从而导致肿瘤增殖、耐药和转移.因此,肿瘤治疗方案理应随着肿瘤的进化过程而变化和调整.然而,现阶段纳米药物的设计对肿瘤进化的临床现实缺乏充分考虑.本文提出靶向肿瘤进化的创新纳米药物的构想,即从肿瘤进化的临床现实出发,尽可能灵敏地、准确地、全面地跟踪肿瘤在自然选择、治疗压力下出现的增殖、耐药、转移等过程,掌握该过程中的进化特征,并基于这些进化特征设计创新纳米药物,能够有策略地、主动地、及时地动态调整纳米药物及给药方案,结合临床上其他多种治疗药物和方法,力争把肿瘤控制为慢性疾病.     

基于透明质酸构筑的药物递送载体及其应用

传统纳米药物控释载体主要通过细胞胞吞作用实现药物递送,其主要过程为被动靶向机制,因此会影响纳米载体在肿瘤组织的富集和治疗效果.近年来生物大分子透明质酸因其优异的水溶性、生物相容性、可降解性和肿瘤靶向性备受科研工作者青睐,已被广泛用于药物控释载体的构筑中,并成为靶向肿瘤治疗纳米载体领域的研究热点.本文根据透明质酸基纳米载...     

多肽介导的肿瘤靶向纳米递药系统

肿瘤靶向纳米递药系统是指利用肿瘤组织特殊的生理病理特点,由纳米载体包载肿瘤诊疗药物构建而成的对肿瘤组织具有靶向定位功能的药物递送系统。多肽介导的肿瘤靶向纳米递药系统是肿瘤靶向递药领域较新的一个研究方向,本文综述了该研究方向的四个重要发展历程——单功能靶向、双功能靶向、肿瘤穿透和环境响应型靶向纳米递药系统,并介绍了各类递药系统的设计原理和典型研究案例。此外,对目前多肽介导的纳米递药系统存在的优势与不足进行了分析。最后,针对当前主动靶向肿瘤递药系统存在的研究困境,提出了一种新型肿瘤靶向递药策略——"系统性靶向"策略。随着相关学科和多学科交叉的发展,多肽介导的肿瘤靶向纳米递药系统将在肿瘤治疗中扮演更为重要的角色。     

Magnetoliposomes as Potential Carriers of Doxorubicin to Tumours

Studies on magnetoliposomes (MLUV) as potential carriers for magnetic‐field‐dependent drug delivery are presented. The systems were formed with hydrophobic superparamagnetic iron oxide nanoparticles (SPIONs) confined within the bilayer of the liposomes. The nanomechanical properties of bilayer lipid membranes were evaluated and related to the amount of incorporated SPIONs. It was found that the presence of SPIONs in the lipid membrane leads to overall stiffening and increases morphological inhomogeneity, facilitating rupture of the MLUV membrane in a low‐frequency alternating magnetic field (AMF). To verify the findings, doxorubicin release from MLUVs in the presence and absence of an AMF was measured. Under experimental conditions, drug release proceeds through MLUV rupture induced by mechanical vibration of SPIONs rather than through localized heating in the vicinity of the SPIONs.     

Development and application of nano-flavor-drug carriers in neurodegenerative diseases

Nano-drug carriers such as liposomes, polymer micelles, and polymer nanoparticles are used for neurodegenerative diseases, which can help drug pass the blood-brain barrier easily, and improve the therapeutic effect.     

天然糖类纳米药物传递系统的研究进展

纳米技术作为影响未来人类生活的世界三大新兴科技之一,其与药物传递系统的融合,既可以将药物的药理作用极大限度地发挥出来,又克服了药物本身的局限性.天然糖类的来源十分广泛,不仅价格低廉、无毒性,且具有良好的生物相容性和生物可降解性,被广泛用于纳米药物传递系统.本文对纳米药物传递系统的体系组成进行了归纳,重点阐述了常见糖类及...     

Functionalization of magnetic nanoparticles with dendritic-linear-brush-like triblock copolymers and their drug release properties

Novel water-soluble dendritic-linear-brush-like triblock copolymer polyamidoamine-b-poly(2-(dimethylamino)ethyl methacrylate)-b-poly(poly(ethylene glycol) methyl ether methacrylate) (PAMAM-b-PDMAEMA-b-PPEGMA)-grafted superparamagnetic iron oxide nanoparticles (SPIONs) were successfully prepared via a two-step copper-mediated atom transfer radical polymerization (ATRP) method. The macroinitiators were immobilized on the surface of Fe(3)O(4) nanoparticles via effective ligand exchange of oleic acid with the propargyl focal point PAMAM-typed dendron (generation 2.0, denoted as propargyl-D(2.0)) containing four carboxyl acid end groups, following a click reaction with 2'-azidoethyl-2-bromoisobutylate (AEBIB). PDMAEMA and PPEGMA were grown gradually from nanoparticle surfaces using the "grafting from" approach, which rendered the SPIONs soluble in water and reversed aggregation. To the best of our knowledge, this is the first report that describes the functionalization of magnetic nanoparticles with dendritic-linear-brush-like triblock copolymers. The modified nanoparticles were systematically studied via TEM, FT-IR, DLS, XRD, NMR, TGA, and magnetization measurements. DLS measurement confirmed that the obtained dendritic-linear-brush-like triblock copolymer-grafted SPIONs had a uniform hydrodynamic particle size of average diameter less than 30 nm. The dendritic-linear-brush-like triblock copolymer-grafted SPIONs possessed excellent biocompatibility by methyl tetrazolium (MTT) assays against NIH3T3 cells and hemolysis assays with rabbit erythrocytes. Furthermore, an anticancer drug, doxorubicin (Dox), was used as a model drug and loaded into the dendritic-linear-brush-like triblock copolymer-grafted SPIONs, and subsequently, the drug releases were performed in phosphoric acid buffer solution pH = 4.7, 7.4, or 11.0 at 37 °C. The results verify that the dendritic-linear-brush-like triblock copolymer-grafted SPIONs possess pH-responsive drug release behavior. The Dox dose of the loaded and free drug required for 50% cellular growth inhibition was 2.72 and 0.72 μm/mL, respectively, according to MTT assay against a Hella cell line in vitro. Therefore, on the basis of its biocompatibility and drug release effect, the modified SPION could provide a charming opportunity to design some excellent drug delivery systems for therapeutic applications.     

Efficient exosome extraction through the conjugation of superparamagnetic iron oxide nanoparticles for the targeted delivery in rat brain

Exosomes possess endogenous attributes and distinct biological functions, and thereby, their uses as drug nanocarriers have attracted increasing attention for biomedical practices. However, to achieve targeted therapeutic purposes, complicated extractions, as well as modifications of exosomes, are involved. Here, based on the use of superparamagnetic iron oxide nanoparticles conjugated exosome (Ex-SPIONs), a facile exosome extraction through magnetism was established. The produced Ex-SPIONs exhibited a uniform size distribution and desirable biocompatibility. Moreover, taking advantage of the magnetic properties of SPIONs, the targeted delivery of Ex-SPIONs was demonstrated in the rat brain. Therefore, the constructed SPIONs functionalized exosome shows promising therapeutic potentials, including the treatment of brain diseases.     

Biodegradable and self-fluorescent ditelluride-bridged mesoporous organosilica/polyethylene glycol-curcumin nanocomposite for dual-responsive drug delivery and enhanced therapy efficiency

Mesoporous organosilica as drug delivery carriers capable of achieving improved cargo release, enhanced biodegradation, and direct imaging with prolonged circulation time and tracking cargo distribution is highly in demand for biomedical applications. Herein, we report a ditelluride-bridged mesoporous organosilica nanoparticle (DTeMSN)/polyethylene glycol-curcumin (PEG-CCM) nanocomposite through coassembly with oxidative/redox and self-fluorescent response. Tellurium is introduced into the silica framework for the first time as a drug delivery vehicle. In this case, the DTeMSNs as an inner core enable disassembly under oxidative and redox conditions via the cleavage of ditelluride bond, facilitating the drug release of doxorubicin (DOX) in a matrix degradation controlled manner. Through the systematical comparison of diselenide-bridged MSNs and DTeMSNs, DTeMSNs exhibit remarkable advantages in loading capacity, drug release, and degradation behavior, thereby significantly affecting the cytotoxicity and antitumor efficacy. The self-fluorescent response of PEG-CCM shell coated on the surface of DTeMSNs can real-timely track the cellular uptake, DOX release, and biodistribution owing to the intrinsic and stable fluorescence of CCM. Moreover, PEG-CCM could prolong circulation time, provide preferable drug accumulation in tumors, and increase antitumor efficacy of DOX-loaded DTeMSNs. Our findings are likely to enrich the family of organosilica that served as fluorescence-guided drug delivery carriers.     

Bioresponsive mesoporous silica nanoparticles for triggered drug release

Mesoporous silica nanoparticles (MSNPs) have garnered a great deal of attention as potential carriers for therapeutic payloads. However, achieving triggered drug release from MSNPs in vivo has been challenging. Here, we describe the synthesis of stimulus-responsive polymer-coated MSNPs and the loading of therapeutics into both the core and shell domains. We characterize MSNP drug-eluting properties in vitro and demonstrate that the polymer-coated MSNPs release doxorubicin in response to proteases present at a tumor site in vivo, resulting in cellular apoptosis. These results demonstrate the utility of polymer-coated nanoparticles in specifically delivering an antitumor payload.     

Advances in Targeting Drug Biological Carriers for Enhancing Tumor Therapy Efficacy

Chemotherapy drugs continue to be the main component of oncology treatment research and have been proven to be the main treatment modality in tumor therapy. However, the poor delivery efficiency of cancer therapeutic drugs and their potential off-target toxicity significantly limit their effectiveness and extensive application. The recent integration of biological carriers and functional agents is expected to camouflage synthetic biomimetic nanoparticles for targeted delivery. The promising candidates, including but not limited to red blood cells and their membranes, platelets, tumor cell membrane, bacteria, immune cell membrane, and hybrid membrane are typical representatives of biological carriers because of their excellent biocompatibility and biodegradability. Biological carriers are widely used to deliver chemotherapy drugs to improve the effectiveness of drug delivery and therapeutic efficacy in vivo, and tremendous progress is made in this field. This review summarizes recent developments in biological vectors as targeted drug delivery systems based on microenvironmental stimuli-responsive release, thus highlighting the potential applications of target drug biological carriers. The review also discusses the possibility of clinical translation, as well as the exploitation trend of these target drug biological carriers.